Close Menu

NEW YORK (GenomeWeb) – A Bay Area company known for using its proprietary protein-engineering platform for industrial applications is turning its attention toward the in vitro diagnostics market.

Specifically, over the last year or so Redwood City, California-based Codexis has been using its platform, called CodeEvolver, to engineer high-performance enzymes for customers using next-generation sequencing and PCR in IVD applications.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.

Jun
02
Sponsored by
NanoString

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics.